EMA (EU)
GUIDANCE FINAL
Draft guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information - Revision 1
Published: 11/9/2026Detected: 11/9/2026
Summary preview
Clarifies how to assess and document risks to fertility, pregnancy, and breastfeeding from non-clinical and clinical data through to final product information in the EU.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – November 202611/12/2026
- Stakeholder Meeting on the transferable data exclusivity voucher (TDEV) for priority antimicrobials11/12/2026
- Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - November 202611/12/2026
- HMA / EMA multistakeholder AI and Data forum: Build trustworthy AI on strong data foundations11/12/2026
- Q&A clinic on Substance, Organisation, Referentials Management Services - November 202611/11/2026